抗革兰阴性细菌感染抗生素的研发新进展

发布时间：2018-05-31 11:36

本文选题：多药耐药 + 革兰阴性细菌　；参考：《药学学报》2013年07期

【摘要】：多药耐药(MDR)的细菌感染,尤其是MDR革兰阴性细菌感染,已经成为全球公共健康最大的威胁之一。然而,新型有效的抗生素研发并没有伴随MDR细菌的增加而增加。数十年来,新批准的抗生素数量在不断减少,治疗MDR革兰阴性细菌感染的抗生素研发在半个多世纪以来更是一直停滞不前。因此,从市场和国民生活安全的角度考虑,对新型抗生素研发的需求就显得非常迫切。虽然目前有一些化合物在体外测试、或在动物模型、甚至在临床研究中显示出一定的活性,但距离批准全面临床应用还较远。所以,全球新型的抗革兰阴性细菌感染的抗生素的供应并不乐观。本文总结了最近几年来国内外针对革兰阴性细菌感染,特别是那些已进入临床试验阶段抗生素的研发进展。除了现有抗生素的衍生物,更希望能引起对与传统抗生素作用机制不同的杀菌剂的关注。
[Abstract]:Multidrug resistant (MDR) bacterial infections, especially MDR Gram-negative bacteria, have become one of the biggest public health threats in the world. However, the development of new and effective antibiotics has not been accompanied by an increase in MDR bacteria. The number of newly approved antibiotics has been dwindling for decades, and the development of antibiotics to treat MDR Gram-negative infections has stagnated for more than half a century. Therefore, from the point of view of market and national life safety, the research and development of new antibiotics is very urgent. Although some compounds are tested in vitro, or in animal models or even in clinical studies, they are still far from being approved for full clinical use. As a result, the global supply of new antibiotics against Gram-negative bacteria is not optimistic. This article summarizes the research and development progress of Gram-negative bacteria infection in recent years, especially those antibiotics that have entered the clinical trial stage. In addition to the existing derivatives of antibiotics, it is expected to attract attention to fungicides that are different from the mechanisms of traditional antibiotics.
【作者单位】： SynChem
【分类号】：R378

【相似文献】